Deborah Baron
President bei TRILLIUM THERAPEUTICS
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Adam Koppel | M | 54 |
Cerevel Therapeutics, Inc.
 Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 6 Jahre |
| Peggy Pinkston | F | - | - | |
| Douglas Giordano | M | 61 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 6 Jahre |
| Ruth McKernan | M | 66 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 4 Jahre |
| Deval Patrick | M | 67 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 4 Jahre |
| Marijn Dekkers | M | 65 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 6 Jahre |
| Norbert Riedel | M | 66 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 6 Jahre |
| N. Coles | M | 63 | 6 Jahre | |
| Ronald Renaud | M | 55 | 1 Jahre | |
| Elaine Heron | M | 76 |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 15 Jahre |
| Suneet Varma | M | 55 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 2 Jahre |
| Christopher Gordon | M | 51 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 6 Jahre |
| Gabrielle Greene-Sulzberger | F | 63 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 5 Jahre |
| Douglas Maffei | M | - | 4 Jahre | |
| Mark Bodenrader | M | 51 | 5 Jahre | |
| Scott Akamine | M | 40 | 3 Jahre | |
| Susan Altschuller | M | 42 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 1 Jahre |
| Andrew Muratore | M | - | 3 Jahre | |
| Kathleen Tregoning | F | 53 | 4 Jahre | |
| Raymond Sanchez | M | 63 | 5 Jahre | |
| John Renger | M | 55 | 5 Jahre | |
| Aaron Schimmer | M | - | - | |
| Jeff Settleman | M | - | - | |
| Anna Robinson | F | - | - | |
| Paul Bien | M | - |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
| Sherry Pudloski | F | - | 1 Jahre | |
| Kenneth DiPietro | M | 65 | 5 Jahre | |
| Chris Boshoff | M | - | 1 Jahre | |
| Paul Burgess | M | 50 | 1 Jahre | |
| Karin Tollefson | M | 57 | - | |
| William Compton | M | - | - | |
| Matthew Calistri | M | - | - | |
| Kathleen Large | F | 64 | 5 Jahre | |
| Natasha Hernday | F | 52 | 13 Jahre | |
| Niall O'Donnell | M | 51 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
| David Caouette | M | - | 3 Jahre | |
| Chris LeMasters | M | - |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 4 Jahre |
| Anand Mehra | M | 48 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
| Alison Marquez O'Neill | F | - | 1 Jahre | |
| Paul Grint | M | 66 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 8 Jahre |
| Guy Padbury | M | - | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Felix Baker | M | 55 | 20 Jahre | |
| Vaughn Himes | M | 63 | 14 Jahre | |
| Jan Skvarka | M | 57 | 2 Jahre | |
| Robert A. Uger | M | 53 | 8 Jahre | |
| James Parsons | M | 58 | 10 Jahre | |
| Luke Beshar | M | 65 | 7 Jahre | |
| Alpna Seth | M | 60 | 5 Jahre | |
| Morris J. Birnbaum | M | 72 | 4 Jahre | |
| Scott Myers | M | 57 | - | |
| Penka Petrova | M | 56 | 8 Jahre | |
| Sandra Swain | M | 70 | 1 Jahre | |
| Charles Romp | M | - | 13 Jahre | |
| Helena Tayton-Martin | M | 57 | 4 Jahre | |
| David Epstein | M | 62 | 1 Jahre | |
| Paul Walker | M | 49 | 1 Jahre | |
| John Orwin | M | 62 | 9 Jahre | |
| Nancy Simonian | M | 63 | 11 Jahre | |
| Daniel Welch | M | 66 | 17 Jahre | |
| Ted Love | M | 65 | 3 Jahre | |
| David Gryska | M | 68 | 18 Jahre | |
| Michael Kamarck | M | 73 | 1 Jahre | |
| Paolo Pucci | M | 63 | 1 Jahre | |
| Jean Liu | F | 55 | 9 Jahre | |
| Roger Dansey | M | 68 | 5 Jahre | |
| Catherine Mackey | M | 68 | - | |
| Todd Simpson | M | 63 | 18 Jahre | |
| Abraham Ceesay | M | 46 | 2 Jahre | |
| Kathy Yi | F | 52 | 2 Jahre | |
| Ingmar Bruns | M | 49 | 1 Jahre | |
| Orly Mishan | F | - | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 55 | 77,46% |
| Kanada | 16 | 22,54% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Deborah Baron
- Persönliches Netzwerk
